@8dragon. ...we should pressure it so that it can come down to 3 cents and below
--------------------------------------------------------------------
No need to wait for 3 sen. You better wait for 1 sen if you think that Nexgram is going to station GN3... What a poor opportunist....

That's why I prefer to relate the covid-19 vaccine deal more on Sputnik V as the JV candidate. I believe that Rafarma's subsidiary in Russia can negotiate for the JV participation in the Malaysian Goverment effort to secure the Sputnik V vaccine for Malaysia... Keep dreaming.. Brother

About to grant contract to their cronies... This one I agree. He He

8dragon. If we rely on your logic, I want to suggest all the plastic/bottle manufacturer in Malaysia to be banned to operate.
After that the goverment of Malaysia should give permission to import plastic goods and bottles tax free.
BUY LOCALL PRODUCT LAST. He He

..... mutually agreed to extend the aforementioned deadline to 15 February 2021 to fulfill the conditions precedent of the Subscription Agreement.

How about ESOS?

The private placement (the last years PP) has been ended on 13.1.2021.

Wariness in Indonesia as Chinese Sinovac COVID-19 jabs start.

"I'm not rejecting vaccines, I'm rejecting Sinovac's," said Yusdeny Lanasakti, an East Java doctor who is worried about the vaccine's efficacy.

Source: https://uk.news.yahoo.com/wariness-indonesia-chinese-sinovac-covid-080953468.html

Yes. Nexgram company is a rubbish collector company. The rubbish will be recycle to be reusable goods. It will has a better earnings and going to be in black again. He He

Better give 3 doses. 50% + 50% + 50% = 150% He He
I personally don't want to have this type of vaccine.....

1. China’s Sinovac COVID-19 Vaccine Less Effective than Initially Thought

Source: https://www.voanews.com/covid-19-pandemic/chinas-sinovac-covid-19-vaccine-less-effective-initially-thought

2. Sinovac's Covid-19 vaccine 78% effective in late-stage trial in Brazil — source
Source: https://www.theedgemarkets.com/article/sinovacs-covid19-vaccine-78-effective-latestage-trial-brazil-%E2%80%94-source

3. New Brazil data shows disappointing 50.4% efficacy for China's CoronaVac vaccine
Source: https://www.theedgemarkets.com/article/new-brazil-data-shows-disappointing-504-efficacy-chinas-coronavac-vaccine

4. Coronavirus: Scientists concerned by way data from Chinese drug firm Sinovac’s vaccine trials is coming out

Source: https://sg.news.yahoo.com/coronavirus-scientists-concerned-way-data-140100178.html

and has an overall efficacy of 50.4 percent in Brazil's final-stage trials.

Sejak dari mula, Sinovac vaccine memang ada masalah dari segi laporan ujian keberkesanannya:

1. China’s Sinovac COVID-19 Vaccine Less Effective than Initially Thought

Source: https://www.voanews.com/covid-19-pandemic/chinas-sinovac-covid-19-vaccine-less-effective-initially-thought

2. Sinovac's Covid-19 vaccine 78% effective in late-stage trial in Brazil — source
Source: https://www.theedgemarkets.com/article/sinovacs-covid19-vaccine-78-effective-latestage-trial-brazil-%E2%80%94-source

3. New Brazil data shows disappointing 50.4% efficacy for China's CoronaVac vaccine
Source: https://www.theedgemarkets.com/article/new-brazil-data-shows-disappointing-504-efficacy-chinas-coronavac-vaccine

4. Coronavirus: Scientists concerned by way data from Chinese drug firm Sinovac’s vaccine trials is coming out

Source: https://sg.news.yahoo.com/coronavirus-scientists-concerned-way-data-140100178.html

Pembekal Sputnik V dari Russia memang mencari partners dari negara lain untuk mengilang vaksin tersebut. Peluang ini terbuka untuk anak syarikat Rafarma di Russia untuk cuba deal untuk JV: . . .....While the Russian Direct Investment Fund (RDIF), which has funded Sputnik V, has deals with multiple countries to supply millions of doses, only about 1.5 million doses of the vaccine have rolled out domestically.
..... The RDIF has said it plans to rely on manufacturing partners in China, India, South Korea and elsewhere to fulfill its major international supply deals

Source: https://news.yahoo.com

New Brazil data shows disappointing 50.4% efficacy for China's CoronaVac vaccine

Source: https://www.theedgemarkets.com/article/new-brazil-data-shows-disappointing-504-efficacy-chinas-coronavac-vaccine

and, for comparison:

As per the release, Sputnik V currently ranks among top 10 candidate vaccines approaching the end of clinical trials and the start of mass production on the World Health Organization's (WHO) list.

The vaccine's efficacy is confirmed at 91.4 per cent based on data analysis of the final control point of clinical trials in Russia, the release said. Currently, the vaccine's clinical trials are underway in the UAE, Egypt, Venezuela and Belarus while it has been registered in Algeria, Argentina, Belarus, Bolivia and Serbia for inoculation.

Source: https://www.newkerala.com/news/2021/6586.htm

Why stagnant at 4.5-5.0 sen with a big volume bid to buy @4.5 sen?
No idea...
No clue...
No answers..???

The new engine of growth for Nexgram..
1. Covid-19 Test Kits (agreement with MKN/MOH and MTC)
2. Covid-19 Test (via subsidiary in Indonesia)
3. Tracvirus SafeTravelPass (Approved by MKN/ MOH))
4. Medical gloves and PPE (gown) (contract with MAPU in Indonesia)
5. NexgramBottleVaccine (via subsidiary operation)
6. RM118 mil Subcontract of the Gua Musang Highway (subcontract in progress)
7. Covid-19 VACCINE (plan to manufacture and distribute (JV with Rafarma))

Informations gathered from the QA at AGM 2020:
1. The company expected to turn profitable earliest in the FY2021.
2. The medical division will potentially contribute to the company growth in near future. A little explanation about the vaccine JV.
3. The Cyberjaya project has been terminated (should be Angkasa Project) caused the big loss in the last QRs (caused by write-off of the land held for property development).
The co also has a plan to use the land for medical center to coop with the medical business expansion.
4. Expected revenues from medical (RM10 mil) and construction (RM28 mil) for FY Ended 31 July 2021.
5. The big losses in 4th QR 2020 is from one-off items. Not to be incurred in the next QR reports.
6. The co is positively believes that the medical and construction will be able to contribute for a better net operating cash flow.
7. On the risk to be GN3 listing issuer. The risk is smaller because medical and construction businesses will help the co to increase the shareholders equity and eliminates the possibility of the co to be listed as GN3 listing co.

@Orlando. Nexgram FA sehingga last QR masih lagi tidak baik. Saya setuju, jika anda menyatakan bahawa pihak bank sukar untuk beri kemudahan margin untuk membeli saham yang FA nya kurang baik. Kalau ada pengecualian pun mungkin untuk sesetengah syarikat tertentu sahaja.

@Orlando. Nexgram belum di senarai sebagai GN3 kerana ianya telah diberi relief untuk satu tahun. Berikut pandangan saya berkaitan risiko GN3 status bagi nexgram:

......Nexgram will not be classified as a GN3 listed issuer and will not be required to comply with the obligations pursuant to Rule 8.04 and GN3 of the ACE LR for a period of 12 months from the date of this announcement. Nexgram will re-assess its condition and announce whether it continues to trigger any of the criteria in GN3 of the ACE LR upon the expiry of the 12 months from the date of this announcement.

1. MUGC untuk tahun kewangan berakhir 2019 inilah yang buat BURSA triger GN3 dalam tahun kewangan berakhir 2020.
Source: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3007846
2. MUGC wujud dalam tahun kewangan berakhir 2019, itulah sebab mengapa ia menjadi calon GN3 berdasarkan MUGC tersebut (tetapi telah DIBERI RELIEF UNTUK SATU TAHUN). Relief tersebut akan dinilai kembali selepas tempoh satui tahun. Bermakna apabila selepas satu tahun dan keadaan yang menyebabkabkan MUCG pada tahun kewangan 2019 pulih, maka Nexgram tidak akan diklasifikasikan di bawah GN3.
4. Sebagai contoh berdasarkan laporan Q1 2021:
Nexgram's share holders equity on consolidated basis of its shares (excluding treasury shares): As per QR1 2021 report = RM108 879 189 / RM 212 519 923 = 51.23 % and As per QR4 2020 report = RM89 221 297 / RM 206 519 923 = 43.20 %
We can see that the percentage of shareholders equity of its shares was increased and surpassed 50%.
5 The company's condition is better in near future, the percentage of shareholders equity of its shares is more than 50%, no more MUGC will be triggered in 2020, no more worry about GN3 listed issuer.
Jadi, GN3 untuk Nexgram dalam jangka pendek ini bagi saya adalah slim chance.

Nexgram said Rafarma will be responsible for the supply of Covid-19 products, while Vaccines Lab will be responsible for assisting the newly-formed joint venture company in its authorisation in target markets, as well as facilitating the registration and conduct of local clinical trials of the products, if necessary.

@8dragon. Pada pandangan saya Nexgram sekarang masih berada DIMEDAN PERANG VAKSIN. Berjaya atau gagal keputusan akhirnya masih belum kita peroleh. HE HE.

@DRwarrant. Hopefully.

The problem is there are sources of infor which did not includes Nexgram as a healthcare/covid-19/covid-19 service provider/player.

Laporan dalam TheEdge berkaitan penglibatan Nexgram dalam Healthcare/Covid-19/Vaksin: SEMUA ADA FASAL HEALTHCARE/COVID-19/VACCINE/GLOVE/PPE....
1. Pharmaniaga Bhd, Bintai Kinden Corp Bhd, Ho Wah Genting Bhd, Solution Group Bhd, Kanger International Bhd, MyEG Services Bhd, Yong Tai Bhd, Nexgram Holdings Bhd and Metronic Global Bhd have announced their vaccine deals. Sumber: https://www.theedgemarkets.com/article/surviving-impact-covid19-healthcare-sector-most-deals

2. Two sub-subsidiaries of Nexgram Holdings Bhd have entered into a deal to facilitate the collection of payment on behalf of the Ministry of Health (MoH) and other government agencies for Covid-19 screening and quarantine involving inbound and outbound travellers. Sumber: https://www.theedgemarkets.com/article/nexgram-appoints-ottigo-payment-collector-covid19-screening
. 3. Nexgram Holdings Bhd, through wholly-owned unit NMED Industries Sdn Bhd (NMEDI), has acquired 65% of Arita Holdings Sdn Bhd (AHSB), which makes plastic materials for the medical equipment market, for RM19.5 million. Source: https://www.theedgemarkets.com/article/nexgram-unit-acquires-65-stake-plastic-material-manufacturer-rm195mil

4. and ICT firm Nexgram Holdings Bhd, which is moving into personal protective equipment and vaccine bottling manufacturing. Source: https://www.theedgemarkets.com/article/cover-story-these-penny-stocks-are-actively-traded-are-they-any-good

5. Interest in Nexgram soared when the loss-making company, whose business is in information and communications technology, property investment and logistics, announced on April 23 its intention to venture into distributing medical ventilators. Through another agreement with Indonesian firm PT Mitra Abadi Propertindo Utama, Nexgram’s unit Nexgram Biomedic Sdn Bhd will sell two million isolation gowns and 500,000 boxes of gloves to the Indonesian partner every month, from November this year to October 2021. There is also an option to extend the deal for 24 months.
Source: https://www.theedgemarkets.com/article/beneficiaries-pandemic-separating-wheat-chaff

6. Medical device provider Nexgram Holdings Bhd (Nexgram) is acquiring medical plastic firm Arita Plastics Industries (M) Sdn Bhd (Arita) to manufacture and supply biomedical materials, life-saving medical devices, medical compounds, and personal protective equipment and plastic sheets as alternative material to borosilicate glass vials for COVID-19 Vaccines. Source: https://www.theedgemarkets.com/article/nexgram-acquires-medical-plastic-firm-enters-vaccine-bottling-business

7. wholly-owned Nexgram Biomedic Sdn Bhd (NBSB) has inked a conditional offtake and purchase agreement with MAPU, under which NBSB will sell PPE — including AAMI isolation gowns powder-free nitrile examination gloves — to MAPU that MAPU will promote, market and distribute in Indonesia. Source: https://www.theedgemarkets.com/article/nexgram-partners-indonesian-firm-sell-ppe-indonesia

TTD1990 Reward will come for those who wait, DrWarrant, glad to see u back
------------------------------------------------------------------
Agreed. I hope so.

Ketiga-tiga kontrak melibatkan safetravelpass oleh Nexgram:

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3119438

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3119917

https://nexgram.co/2020/11/11/safetravelpass-for-malaysia-inbound-travellers-government-system-integrator-contract-gsic-awarded-to-ottigo-collecting-payment-on-behalf-of-moh-for-inbound-travellers-covid-19-screening-test/

MENUNJUKKAN NEXGRAM ADALAH PIONEER DARI SEGI PERKHIDMATAN SAFETRAVELPASS DAN TRACVIRUS. DAN IANYA MENGATASI MYEG DALAM MENYEDIAKAN KHIDMAT YANG SAMA.

PENCAPAIAN YANG BAIK UNTUK NEXGRAM.

8dragon When Nexgram classified under GN3, 3 cents and below definitely materialize...
06/01/2021 9:39 AM
----------------------------------------
@8dragon.
1. MUGC untuk tahun kewangan berakhir 2019 inilah yang buat BURSA triger GN3 dalam tahun kewangan berakhir 2020.

Source: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3007846

2. MUGC wujud dalam tahun kewangan berakhir 2019, itulah sebab mengapa ia menjadi calon GN3 berdasarkan MUGC tersebut (tetapi telah DIBERI RELIEF UNTUK SATU TAHUN). Relief tersebut akan dinilai kembali selepas tempoh satui tahun. Bermakna apabila selepas satu tahun dan keadaan yang menyebabkabkan MUCG pada tahun kewangan 2019 pulih, maka Nexgram tidak akan diklasifikasikan di bawah GN3.

4. Sebagai contoh berdasarkan laporan Q1 2021:

Nexgram's share holders equity on consolidated basis of its shares (excluding treasury shares): As per QR1 2021 report = RM108 879 189 / RM 212 519 923 = 51.23 % and As per QR4 2020 report = RM89 221 297 / RM 206 519 923 = 43.20 %

We can see that the percentage of shareholders equity of its shares was increased and surpassed 50%.

5 The company's condition is better in near future, the percentage of shareholders equity of its shares is more than 50%, no more MUGC will be triggered in 2020, no more worry about GN3 listed issuer.

Jadi, GN3 untuk Nexgram dalam jangka pendek ini bagi saya adalah slim chance.

SafeTravelPass and Tracvirus services locally and internationally:

A. COVID-19 Screening Tests and Quarantine Charges for Traveller Coming Into Malaysia
TracVirus SafeTravelPass is a COVID-19 screening and accommodation arrangement service with the approval of Majilis Keselamatan Negara (MKN). This service is open to both Malaysians and non-Malaysians, and aims to provide a fast, safe, and seamless process for travellers coming into Malaysia.

Source: https://safetravelpass.tracvirus.com.my/

B. “SafeTravelPass”, “MySafeTravel”, or “MyTravelPass” are white labels, brands, franchises of “Tracvirus E-Certificate” worldwide. Copyright (c) 2020. All Rights Reserved. Get your Tracvirus E-Cert today, visit safetravelpass.tracvirus.com

### Can be used internationally:
Singapore . Indonesia . Malaysia . Arab Saudi . China . Hong Kong . Taiwan . Japan . Korea . Australia . New Zealand . Thailand . Cambodia . Myanmar. Vietnam . Philippines | I’m Tracvirus Verified.
Source: https://safetravelpass.com/

C. https://tracvirus.com/ - Conducted in Malaysia
https://tracvirus.co.id/ - Conducted in Indonesia

myeg, hong seng

A. Sputnik V vaccine has been approved in Russia, Belarus and Argentina and Algeria is set to follow them in January. India also waiting to approve at least three more vaccines - local company Bharat Biotch's COVAXIN, Zydus Cadila's ZyCoV-D and Russia's Sputnik-V.

Sources: 1. https://sg.style.yahoo.com/50-countries-start-covid-19-134206907.html
2. https://www.bbc.com/news/world-europe-53735718
3. https://uk.news.yahoo.com/india-approves-astrazenecas-covid-19-101702292.html


B. "Nothing is stopping us producing the components of the vaccine themselves at facilities in foreign states,"

Source: https://www.theedgemarkets.com/article/putin-says-he-will-receive-covid19-vaccine-when-he-can-urges-mass-vaccination

Russia menggalakkan Sputnik V dikilang di negara lain.
... India will produce about 300 million doses of the Russian Sputnik V vaccine. The production of Sputnik V began in other countries, in particular in India, Korea, Brazil and China. Also, Turkey aims to produce Russia's Sputnik V COVID-19 vaccine domestically but has asked for more information about it

Peluang ini sepatutnya diambil oleh JV VaccineLab-Rafarma untuk dapatkan hak pengeluaran di Indonesia untuk pasaran Indonesia dan ASEAN.

Cuma hakikatnya, persaingan untuk Covid-19 vaksin ini amat sengit......

Happy New Year to DRwarrant and all friends..

Bare AAA+. Stim sokmo. He He

ALSO ANOTHER POSSIBILITY:

In addition to the talks with Russia's Gamaleya Institute, the developer of the Sputnik V Vaccine, Malaysia is also in discussions with Chinese manufacturers Sinovac Biotech Ltd and CanSino Biologics to purchase their vaccines.

The deals with the Chinese and Russian manufacturers will include cooperation with Malaysian companies to carry out fill-and-finish work, Khairy said.

Source: https://www.theedgemarkets.com/article/govt-talks-secure-more-vaccines-russia-pfizer-says-khairy

STILL A POSSIBILITY:

Vaccine Lab JV Rafarma Pharmaceuticals (US) + R. & D. Biocogency Laboratories Inc. (Cyprus) + subsidiary of Rafarma, PJSC Kraspharma (Russia) ———-> Russian or other source country Covid-19 vaccine ———> Indonesia and the ASEAN countries

https://news.yahoo.com/turkey-says-aims-produce-russias-122244828.html

https://www.thestar.com.my/news/world/2020/12/21/belarus-registers-sputnik-v-vaccine-in-first-outside-russia---rdif .

https://sg.news.yahoo.com/argentina-launches-covid-19-vaccines-150726888.html

https://uk.news.yahoo.com/russia-supply-bolivia-2-6-154601972.html

In this QR 1, 2021, Arita's contribution still not included yet, any contribution from Glove and PPE (gowns) contract with MAPU also not included yet and any contribution from construction of Gua Musang Highway also not included yet.

QoQ - 95.53% YoY - -4,077.61%

Boss tak suka glamour. Tak nak kawan dgn reporter. The edge keluar berita kemudian padam. He He

8dragon QR report in red again, no wonder counter can't move..
---------------------------

We can confirm it today or tomorrow...
Just waiting for the QR release...

@jennyhee. Please read carefully:

...nexgram will start rally on jan after all vaccines start hot
***** (I believe it also depend on the incoming result of QR 1, 2021)

...paktua aimed rm 0.50 on april (personal target yer)
***** (I believe it depend on the actual results of the company's ability to secure the vaccine
business)

Repost posting paktua73 yang terawal semasa dia join group NXGRAM. {{{{Dengan andaian keadaan tidak berubah}}}}. He He. . . paktua73, [12.12.20 10:16]
morning all nxgram warriors..
after paktua study the rally pattern for nxgram..
this paktua own personal view..

nexgram will start rally on jan after all vaccines start hot

paktua will start fight here on mid jan


paktua73, [12.12.20 10:18]
paktua aimed rm 0.50 on april (personal target yer)

@OKU_2020. It's okay. I'm kuli only.. He He

Stock: [KANGER]: KANGER INTERNATIONAL BHD

Dec 22, 2020 8:48 AM | Report Abuse

morning all..
hope all happy happy..

thanks dk2866..
Paktua cuti sampai 4 jan..
no trade just chit chat only


tut tut
selamat hari natal..

Tik Tok. Tik Tok. Tik Tok...

The company with NTA 0.1277 and the accumulated loss only 2.686 mil, how can be a GN3 list? Any other risk?

Agree. For me, the share price appreciation also will depend on whether the company can secure any Covid-19 vaccine business or not.

If its only depend on the current new businesses (test kit, tracvirus/safetravelpass,gloves, PPEs (gowns) and the Gua Musang subcontact), I think the price appreciation won't be to high.

As for 2021, the hype for Covid-19 vaccines counters will still kicking. If Nexgram can secure any Covid-19 vaccine business, whether it is for bottling or securing The VaccineLab-Rafarma JV, the price of the Nexgram's shares will be BOOM at an unexpected level He He

The Jan 2021 - April 2021 period will be the interesting period to be monitored concerning the prospect of Nexgram in securing Covid-19 vaccine business.

With the emergence of Rafarma Pharmaceuticals and its Russian subsidiary PJSC Kraspharma as a JV partner with VaccineLabs, Nexgram has a great chance to cater for the Russian Gamaleya Sputnik V vaccine business (in Malaysia or Indonesia).

My great dreams for Nexgram. He He

TracVirus has been facilitated MORE THAN 400,000 Covid-19 tests in Malaysia throughout the year 2020.
Source: Tracvirus.com (APP)

Not to forget, TracVirus also facilitated the Covid-19 test sevices in Indonesia via Nexgram's subsidiary PT NDS Global Teknologi. (No data for the number of tests conducted can be retrieved)
Source: Tracvirus.co.id

And let us not to forget, the probable new FUTURE ENGINE of growth for Nexgram:

....... Covid-19 VACCINE to manufacture and distribute from a JV with Rafarma.

When the Financial Statements of the company is better,
and the development of projects and future prospects of profitability of the company is gained.
the TRUST on the company will grow, THE PRICE MUST BE APPRECIATED.

-------------------------------------------------------------------

The new engines of growth for Nexgram..

1. Covid-19 Test Kits (agreement with MKN/MOH and MTC)
2. Covid-19 Test (via subsidiary in Indonesia)
3. Tracvirus SafeTravelPass (Approved by MKN/ MOH))
4. Medical gloves and PPE (gown) (contract with MAPU in Indonesia)
5. NexgramBottleVaccine (via subsidiary operation)
6. RM118 mil Subcontract of the Gua Musang Highway (subcontract in progress)